WHO CAN SIGN UP?

Individuals younger than 65 with mild cognitive impairment (MCI) or dementia of mild severity suspected to be caused by Alzheimer’s disease can sign up. In addition, the study is seeking a small number of individuals younger than 65 who do not have any cognitive impairment. Those who have progressed to moderate or severe dementia are not a good fit for LEADS.

You may be eligible if:

» You are between the ages of 40 and 64.

» You are fluent in English.

» You are in good general health and have not experienced another neurologic disorder.

» You have a family member, friend or caregiver who can provide additional information about your lifestyle.

alzheimer’s association®

The Alzheimer’s Association is the leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research: to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.

Our vision is a world without Alzheimer’s disease®.

800.272.3900 | alz.org®

This is an official publication of the Alzheimer’s Association but may be distributed freely and without charge by unaffiliated organizations and individuals. Such distribution does not constitute an endorsement of these parties or their activities by the Alzheimer’s Association.
Alzheimer’s disease is a national crisis, with more than 5 million Americans living with the disease and 16 million friends and family acting as caregivers. In addition, more than 200,000 individuals with Alzheimer’s are under age 65, meaning they have the early-onset form of the disease.

The Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) explores the development of early-onset Alzheimer’s disease and how it compares to the more common late-onset Alzheimer’s variant.

To move toward more effective treatments, scientists need to understand the genetic, biological and clinical processes involved in early-onset Alzheimer’s disease. Your participation in LEADS could create future medical advances to help all those affected by Alzheimer’s disease.

**STUDY PARTICIPATION**

Your ongoing participation is critical to the success of LEADS. Participants will perform study activities at the beginning of their involvement, at the mid-point one year later, and finally two years later, for a total of three visits.

**STUDY ACTIVITIES INCLUDE:**

- General medical and neurologic exams.
- Cognitive testing.
- Biofluid sample collection (blood and optional spinal fluid samples).
- Neuroimaging (MRI and PET scans).

**LOCATIONS**

LEADS is enrolling participants at research sites across the country. For a complete listing of sites, visit [alz.org/LEADS](http://alz.org/LEADS) or [LEADS-study.org](http://LEADS-study.org).

**HOW TO ENROLL**

By participating in LEADS, you will play a key role in advancing early-onset Alzheimer’s research to support future treatment options. To learn more and sign up:

- Visit [alz.org/LEADS](http://alz.org/LEADS) or [LEADS-study.org](http://LEADS-study.org).
- Call 877.385.3237 (877.38LEADS).
- Contact an enrolling site near you.

Protocol 1801979770 IRB Approved